ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo

ALPCO will promote the expansion of its STELLUX® Chemiluminescence ELISA platform, as well as its current therapeutic drug monitoring portfolio, gastroenterology testing panel, and assay qualification program at AACC’s 70th Annual Clinical Lab Expo.

ALPCO to Exhibit at the AACC’s 70th Annual Scientific Meeting and Clinical Lab Expo
Salem, NH, July 25, 2018 --( ALPCO, a leading producer of research and clinical immunoassays, announced it will exhibit at the AACC’s 70th Annual Clinical Lab Expo July 31 - August 2, 2018 in Chicago, IL. The company will promote a number of tools to help research and improve clinical outcomes as well as increase laboratory efficiency.

Among these tools are new and upcoming additions to ALPCO’s STELLUX® Chemiluminescence product line including fecal calprotectin, active GLP-1 (7-36) amide, and glucagon ELISAs. ALPCO is currently conducting ongoing clinical studies with the STELLUX® Chemiluminescence Calprotectin ELISA to establish the kit as a future tool for the diagnosis of Crohn's disease and ulcerative colitis.

ALPCO will also promote its comprehensive therapeutic drug monitoring portfolio consisting of ten colorimetric ELISAs. The therapeutic drug monitoring assays offer a reliable method to research optimal concentrations, immune responses, and the influence of anti-drug antibodies on biologics which can lead to improving clinical outcomes for inflammatory bowel disease.

Laboratory professionals can visit ALPCO at the Clinical Lab Expo to learn about maximizing lab productivity with ALPCO’s complete gastroenterology ELISA testing panel and the FDA Class I Exempt Easy Stool Extraction Device. By using both tools together, lab technicians can replace manual weighing with one simple extraction step, while increasing the efficiency and reliability of measuring biomarkers such as pancreatic elastase-1.

In addition, AACC Clinical Lab Expo attendees can learn about ALPCO’s assay qualification program which assists laboratories with transitioning to in-house testing.

“Our assay qualification program was developed to help institutions save time and ease the burden of onboarding new tests,” said ALPCO President Sean Conley. “Ultimately, our aim is to allow for savings that will result in lower overall healthcare costs in the industry.”

Visit ALPCO in booth 3467 at the AACC’s 70th Annual Clinical Lab Expo to learn more about these tools and services to help improve clinical outcomes and increase productivity in the lab.

American Laboratory Products Company (ALPCO) was founded in 1991 as an importer and distributor of immunoassay-based products for the North American life science markets. The company has since grown into a premier channel representing over 60 collaborating partners from around the globe. Today, ALPCO offers a wide range of testing solutions, providing scientists and healthcare professionals with vital tools for advancing research and improving quality of care.
Bethany Bell, PhD